Analysts Offer Insights on Healthcare Companies: Mirati Therapeutics (MRTX) and Progenics (PGNX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirati Therapeutics (MRTX) and Progenics (PGNX) with bullish sentiments.

Mirati Therapeutics (MRTX)

In a report issued on March 1, Chris Shibutani from Cowen & Co. maintained a Buy rating on Mirati Therapeutics. The company’s shares closed yesterday at $72.19, close to its 52-week high of $79.31.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.7% and a 47.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Nektar Therapeutics, and United Therapeutics.

Currently, the analyst consensus on Mirati Therapeutics is a Moderate Buy with an average price target of $78, implying an 8.0% upside from current levels. In a report issued on February 15, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $85 price target.

See today’s analyst top recommended stocks >>

Progenics (PGNX)

Brookline Capital Markets analyst Kumaraguru Raja reiterated a Buy rating on Progenics yesterday and set a price target of $12. The company’s shares closed yesterday at $4.26, close to its 52-week low of $3.62.

According to TipRanks.com, Raja is a 1-star analyst with an average return of -4.1% and a 48.0% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Acer Therapeutics Inc, and Heat Biologics.

Progenics has an analyst consensus of Moderate Buy, with a price target consensus of $9.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts